RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $165

Benzinga Newsdesk www.benzinga.com Positive 92.5%

Neg 0% Neu 0% Pos 92.5%

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $162 to $165.